Keros Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference

Rhea-AI Summary

Keros Therapeutics, Inc. (Nasdaq: KROS), a biopharmaceutical company, announced that its President and CEO Jasbir S. Seehra, Ph.D., will participate in a fireside chat at Cowen’s 43rd Annual Health Care Conference on March 8, 2023, at 11:10 a.m. Eastern time. The event will provide insights into Keros’ innovative treatments for hematological, pulmonary, and cardiovascular disorders. A live audio webcast can be accessed here, with an archived replay available on Keros’ website for up to 90 days post-event.

LEXINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at Cowen’s 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 11:10 a.m. Eastern time.

A live audio webcast of the fireside chat presentation will be available at https://wsw.com/webcast/cowen132/kros/2037294 and an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of the event.

About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-beta family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of a number of tissues, including blood vessels and heart tissue. Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of functional iron deficiency. Keros’ third product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders.

Investor Contact:
Justin Frantz
jfrantz@soleburystrat.com     
617-221-9100

FAQ

What is Keros Therapeutics' participation in the Cowen Health Care Conference?

Keros Therapeutics will have its President and CEO, Jasbir S. Seehra, Ph.D., participate in a fireside chat at the Cowen’s 43rd Annual Health Care Conference on March 8, 2023.

When is Keros Therapeutics' presentation scheduled at the Cowen Conference?

The presentation is scheduled for March 8, 2023, at 11:10 a.m. Eastern time.

How can I listen to Keros Therapeutics' fireside chat?

You can access the live audio webcast of the fireside chat at Keros' investor relations page or directly through Cowen's webcast portal.

What products is Keros Therapeutics developing?

Keros is developing several product candidates, including KER-050 for cytopenias, KER-047 for functional iron deficiency, and KER-012 for pulmonary arterial hypertension.

What is Keros Therapeutics known for?

Keros Therapeutics specializes in novel treatments for hematological, pulmonary, and cardiovascular disorders with significant unmet needs.